11 studies on Pinealon curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 316 published third-party lab tests of Pinealon across 161 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.43%. Within this published corpus, 1 positive purity result was below 90%, and 24 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $8.67 | $2.00–$12.00 | $0.87 | 3 sources · 3 offers |
| 20 mg | $19.50 | $19.50–$19.50 | $0.97 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 58 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 15 | 99.48% | 0 of 14 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #2 | 12 | 99.53% | 0 of 10 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #3 | 6 | 99.62% | 0 of 5 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #101209 (99.65%) · #101158 (99.93%) · #100254 (99.81%) · #100754 (99.33%) · #99531 (99.82%) · #100555 (99.91%)
These findings are significant as they highlight the potential of peptide preparations like Cortexin and Pinealon as geroprotective agents, capable of enhancing brain resilience against age-related stressors. By modul…
This research underscores the significant potential of specific oligopeptides, particularly the combination of Vezugen and Pinealon, as highly effective and safe geroprotective agents. The superior impact on biologica…
The introduction of the short peptides generally promoted a survival rate in animals subjected to carotid artery occlusion, though specific quantitative data for this improvement was not provided. > The study found th…
Pinealon's dual action of reducing oxidative stress and modulating cell proliferation highlights its potential as a therapeutic agent for conditions involving cellular damage and impaired regeneration. The finding tha…
This research confirms the neuroprotective properties of Pinealon, extending previous in vitro findings to an in vivo model of prenatal stress. The ability of Pinealon to protect against cognitive impairment and oxida…
This research suggests a novel strategy for maintaining the professional reliability and long-term health of individuals exposed to demanding work environments. The positive impact of Pinealon on biological age and ad…
This research highlights the significant potential of these bioregulatory tripeptides, particularly T-38, as novel agents for enhancing skin regeneration and combating age-related skin pathologies. The ability of T-38…
This research underscores the potential of peptide geroprotectors as novel therapeutic agents for combating age-related cognitive decline and neurodegenerative diseases. The finding that Pinealon exerts a prevalent po…
These findings are significant as they highlight the potential of specific peptides to mitigate the damaging effects of oxygen deprivation in the aging brain. Pinealon's capacity to both stimulate neurogenesis and red…
This research provides critical insights into the molecular mechanisms governing peptide-DNA interactions, particularly highlighting the significant and specific role of divalent ions like magnesium. Such detailed und…
The characterization of Pinealon as a neuroprotective tripeptide is highly significant, as it points towards a potential endogenous mechanism for maintaining brain health and resilience. This understanding could be fo…
Free, no account — handy when you're working with Pinealon.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$12 monthly or $33 lifetime
Create free account